Nitric Oxide (NO) is an important cellular signaling molecule that participates in functions such as vasodilation, smooth muscle relaxation, neurotransmission, and the immune response. iNOS is only expressed when the cell is induced or stimulated ( thus known as inducible nitric oxide synthase), by pro-inflammatory cytokines and/or bacterial lipopolysaccharide, and upon induction, iNOS generates a significant amount of NO, which helps to defend against invading pathogens, however, the overexpression or dysregulation of iNOS can result in toxic effects, including septic shock, cardiac dysfunction, pain, diabetes, and cancers. iNOS inhibitors either directly reversibly inhibit L-Arg binding or compete with L-Arg and then irreversibly inactivate the enzyme in a time, concentration, or NADPH-dependent manner. iNOS inhibitors are indicated for allergic conjunctivitis, asthma, cerebrovascular disorders, hypotension, and others. MediciNova, GSK, GC Biopharma, Ono Pharma, Pfizer, Viatris, and TrioxBio are some of the major players in the iNOS inhibitors market.
Key Market Developments:
- In Mar 2023, MediciNova extended the contract with BARDA to repurpose Ibudilast against chlorine-gas-induced lung damage such as acute respiratory distress syndrome and acute lung injury.
- In May 2023, MediciNova received notice of intention to grant a patent for Ibudilast in microorganism infection in Europe.
Approved Drug Molecules and Brand Names for iNOS Inhibitors:
- Eyevinal (Ibudilast)
- Doxycycline delayed-release
- Shinbaro (GCSB-5)
- S-ethylisothiuronium diethylphosphate (MTR-105)
Drugs under the Pipeline for iNOS Inhibitors:
- Bardoxolone methyl (RTA 402)
- GW-274150
- Cereact (Arundic acid)
- Diacerein controlled release (AC 201)
- NXN-188
- Ronopterin (VAS203)
- Cindunistat (SC84250)
- CR 3294
- KD-7040
- NXN-462
- Zevaquenabant (INV-101)
Clinical Activity and Developments of iNOS Inhibitors:
Currently, there are a total of 15 drug products in the iNOS inhibitors, including 4 approved drug products and the rest of them are in the clinical development phases.
- In Jun 2021, Vasopharm BIOTECH released efficacy data from a phase-III NOSTRA-III trial in brain injury for Ronopterin.
- In Jun 2023, Mediciova presented the efficacy data from a phase-IIb trial in alcoholism for Ibudilast.
|
Molecule Name |
Number of Studies |
|
Bardoxolone methyl (RTA 402) |
37 |
|
GW-274150 |
6 |
|
Cereact (Arundic acid) |
5 |
|
Diacerein controlled release (AC 201) |
4 |
|
NXN-188 |
3 |
|
Ronopterin (VAS203) |
3 |
|
Cindunistat (SC84250) |
2 |
|
CR 3294 |
1 |
|
KD-7040 |
1 |
|
NXN-462 |
1 |
|
Zevaquenabant (INV-101) |
1 |
Target Indication Analysis of iNOS Inhibitors:
iNOS inhibitorsIbudilast has been marketed for the treatment of allergic conjunctivitis, asthma, and cerebrovascular disorders, is in phase-III for spinal cord disorders, in phase-II/II for amyotropic lateral sclerosis, in phase-II for alcoholism, multiple sclerosis, opioid-related disorders, SARS-coV-2 acute respiratory diseases, substance-related disoredrs, in phase-I/II for chemotherapy induced damage, glioblastoma, and in pahse-I for adult respiratory distress syndrome, cytokine release syndrome, and sepsis.
Regional Analysis of iNOS Inhibitors
iNOS Inhibitors Market
According to a study report, allergic conjunctivitis symptoms are present in 30-71% of patients with allergic rhinitis, and allergic conjunctivitis alone was estimated in 6-30% of the general population and in up to 30% of children. According to the World Health Organization, asthma affected an estimated 262 million people in 2019, and caused 4,55,000 deaths. According to the American Heart Association, in 2020, there were 7.08 million deaths attributed to cerebrovascular disease, including 3.48 million deaths from ischemic stroke, 3.25 million deaths from intracerebral hemorrhage, and 0.35 from subarachnoid hemorrhage, with the highest mortality rate in Oceania, Central Asia, Latin America, and Eastern Europe. With the growing burden of disease rates, the iNOS inhibitors market is also expected to grow.
Latin America
Europe
Asia Pacific
Middle East
North America
Frequently Asked Questions
Eyevinal (Ibudilast), Shinbaro (GCSB-5), and S-ethylisothiuronium diethylphosphate (MTR-105) are some of the approved iNOS inhibitors.
MediciNova, GSK, GC Biopharma, Ono Pharma, Pfizer, Viatris, and TrioxBio are some of the major players in the iNOS inhibitors market.
Major indications for iNOS inhibitors are allergic conjuctivitis, asthma, cerebrovascular diorders, and hypotension.
There are a total of 11 molecules in the clinical development phases for iNOS inhibitors.
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
- Kyowa Kirin
- MediciNova
- GSK
- GC Biopharma
- Ono Pharma
- TWi Pharma
- NeurAxon
- Vasopharm BIOTECH
- Pfizer
- Viatris
- NeurAxon
- TrioxBio
- Inversago Pharma